Business
Magenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results
– MGTA-117 ADC clinical candidate for immune and blood system reset has demonstrated broad therapeutic index; on track for initial clinical data in 2021 – –
About this update from Dianthus Therapeutics, Inc.
[{"type":"text","content":"\n– MGTA-117 ADC clinical candidate for immune and blood system reset has demonstrated broad therapeutic index; on track for initial clinical data in 2021 –\n\n\n– Announced research and clinical collaboration with AVROBIO to evaluate potential utility of MGTA-117 antibody-drug conjugate (ADC) as conditioning regimen in gene therapy setting – \n\n\n– Completed dosing in Phase 1 MGTA-145 trial, demonstrating rapid, same-day first line stem cell mobilization and collection; met all primary and secondary endpoints; potential for initial Phase 2 data in 2020 –\n\n\n– Phase 2 trial of MGTA-456 in inherited metabolic disorders experiencing COVID-19-related enrollment delay; Phase 2 trial of MGTA-456 in blood cancers expected to complete enrollment in 2020 –\n\n\n– Ended quarter with $130.4 million in cash, cash equivalents and marketable securities, and cash runway extended to 1Q 2022 –\n\n\n– Company to hold investor conference call at 8:00 a.m. ET -\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\n\nMagenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported recent business highlights and financial results for the first quarter ended March 31, 2020.\n\n\n“The first quarter of 2020 has shown Magenta to be well-positioned to advance our programs and to weather unexpected obstacles. Magenta continues to execute and progress our pipeline, and we remain committed wholeheartedly to our patients, their families, our employees and our business partners,” said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta. “In this first quarter, Magenta has showcased significant clinical and preclinical results, and we are building on these results to advance quickly.”\n\n\nRecent Business Highlights:\n\n\nMGTA-117 lead clinical candidate for conditioning for stem cell transplant and gene therapy demonstrates broad therapeutic index; advancing MGTA-117 to deliver initial clinical data in 2021. Data presented at the Transplant and Cellular Therapies (TCT) conference in February 2020 demonstrated that MGTA-117’s optimized linker payload resulted in potent depletion of stem and progenitor cells with an improved therapeutic index of 30 (range for approved ADCs at this stage of development has been two- to six- fold). The ADC i...